First Patient Receives Leqembi Treatment in Sweden, Marking a Milestone in Alzheimer's Care
In a remarkable leap forward for Alzheimer's treatment in Sweden, BioArctic AB has announced that the first patient has begun receiving Leqembi® (lecanemab) at a private clinic. This marks a significant step as it is the first instance of a patient being treated with Leqembi outside of a clinical trial setting since it received European Union approval in April 2025. Gunilla Osswald, CEO of BioArctic, expressed her elation by stating, "I am very happy that we are now starting to help people diagnosed with early Alzheimer's disease in Sweden as well. There is a significant unmet need for new treatment options that slow the progression of Alzheimer's disease from its early stages." This sentiment underscores the urgent need for innovative treatments, highlighting the burden that Alzheimer's imposes not just on patients, but also on caregivers and healthcare systems.
Leqembi was developed as a result of extensive research focused on the underlying causes of Alzheimer’s disease. As noted by BioArctic, it specifically targets amyloid-beta, which is implicated in the disease’s progression. With its approval in the EU as the first therapy aimed at this fundamental cause of Alzheimer's, it has set a precedent for future treatments. Additionally, Leqembi has garnered approval in 53 countries and is under regulatory review in six others, reflecting its potential to become a global solution to an increasingly common ailment.
After its EU approval, efforts to facilitate patient access in Sweden were put into place; however, challenges remained. In April 2026, the New Therapies Council (NT-rådet) issued a negative recommendation regarding its inclusion in the publicly funded healthcare system. Despite this setback, Executive Health in Stockholm committed to providing the necessary treatment for those suffering from early-stage Alzheimer's. The journey of Leqembi is notable not only for its scientific contributions but also for its commercial collaboration between BioArctic and Eisai. This partnership has been pivotal in bringing the drug to market, with Eisai responsible for its clinical development and global commercialization. BioArctic retains rights to market the drug within the Nordic region, allowing them to make a meaningful impact on the local healthcare landscape.
The story of Leqembi is built upon over two decades of rigorous research, stemming from Professor Lars Lannfelt’s pioneering work at Uppsala University. It serves as a testament to the importance of investment in science and innovation aimed at combating diseases that significantly affect quality of life. As BioArctic aims to address other neurodegenerative conditions, such as Parkinson's and ALS, Leqembi seems to be a crucial first step towards broader advancements in medical treatments within the realm of neurological disorders. All stakeholders are eager to see how this new treatment will affect the lives of patients in Sweden and beyond and what it could mean for the future approach to Alzheimer's disease management. As this first patient starts the treatment, it opens discussions about widespread access and the potential benefits for many more individuals afflicted with early Alzheimer's disease.
Leqembi was developed as a result of extensive research focused on the underlying causes of Alzheimer’s disease. As noted by BioArctic, it specifically targets amyloid-beta, which is implicated in the disease’s progression. With its approval in the EU as the first therapy aimed at this fundamental cause of Alzheimer's, it has set a precedent for future treatments. Additionally, Leqembi has garnered approval in 53 countries and is under regulatory review in six others, reflecting its potential to become a global solution to an increasingly common ailment.
After its EU approval, efforts to facilitate patient access in Sweden were put into place; however, challenges remained. In April 2026, the New Therapies Council (NT-rådet) issued a negative recommendation regarding its inclusion in the publicly funded healthcare system. Despite this setback, Executive Health in Stockholm committed to providing the necessary treatment for those suffering from early-stage Alzheimer's. The journey of Leqembi is notable not only for its scientific contributions but also for its commercial collaboration between BioArctic and Eisai. This partnership has been pivotal in bringing the drug to market, with Eisai responsible for its clinical development and global commercialization. BioArctic retains rights to market the drug within the Nordic region, allowing them to make a meaningful impact on the local healthcare landscape.
The story of Leqembi is built upon over two decades of rigorous research, stemming from Professor Lars Lannfelt’s pioneering work at Uppsala University. It serves as a testament to the importance of investment in science and innovation aimed at combating diseases that significantly affect quality of life. As BioArctic aims to address other neurodegenerative conditions, such as Parkinson's and ALS, Leqembi seems to be a crucial first step towards broader advancements in medical treatments within the realm of neurological disorders. All stakeholders are eager to see how this new treatment will affect the lives of patients in Sweden and beyond and what it could mean for the future approach to Alzheimer's disease management. As this first patient starts the treatment, it opens discussions about widespread access and the potential benefits for many more individuals afflicted with early Alzheimer's disease.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.